Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate

International Journal of Antimicrobial Agents

Volumn 48, Issue 6, 2016, Pages 725-727

  Horcajada, Juan P ^a   Sorlí, Luisa ^a   Luque, Sonia ^b   Benito, Natividad ^c,d,e   Segura, Concepción ^f   Campillo, Nuria ^b   Montero, Milagro ^a   Esteve, Erika ^a   Mirelis, Beatriz ^c   Pomar, Virginia ^c,d,e   Cuquet, Jordi ^g   Martí, Carmina ^g   Garro, Pau ^g   Grau, Santiago ^b  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

^f Laboratori de Referencia de Catalunya   (Spain)

^g Granollers General Hospital   (Spain)

Author keywords

Colistin; Nephrotoxicity; Plasma concentration; Risk factors; Therapeutic drug monitoring

Indexed keywords

COLISTIMETHATE; COLISTIN; ANTIINFECTIVE AGENT; COLISTINMETHANESULFONIC ACID;

ADULT; AGE; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; GRAM NEGATIVE INFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; OBSERVATIONAL STUDY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; VALIDATION STUDY; ACUTE KIDNEY FAILURE; ADOLESCENT; ANALOGS AND DERIVATIVES; CHEMISTRY; CLINICAL TRIAL; DRUG MONITORING; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITAL; MIDDLE AGED; PLASMA; VERY ELDERLY; YOUNG ADULT;

ACUTE KIDNEY INJURY; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLISTIN; DRUG MONITORING; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HOSPITALS; HUMANS; MALE; MIDDLE AGED; PLASMA; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 85000978519     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2016.08.020     Document Type: Article

References (12)

1. [1] Montero, M., Horcajada, J.P., Sorlí, L., Alvarez-Lerma, F., Grau, S., Riu, M., et al. Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. Infection 37 (2009), 461–465.
2. [2] Falagas, M.E., Kasiakou, S.K., Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care, 10, 2006, R27.
3. [3] Pogue, J.M., Lee, J., Marchaim, D., Yee, V., Zhao, J.J., Chopra, T., et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 53 (2011), 879–884.
4. [4] Sorli, L., Luque, S., Grau, S., Berenguer, N., Segura, C., Montero, M.M., et al. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis, 13, 2013, 380.
5. [5] Kim, J., Lee, K.H., Yoo, S., Pai, H., Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents 34 (2009), 434–438.
6. [6] Falagas, M.E., Rafailidis, P.I., Ioannidou, E., Alexiou, V.G., Matthaiou, D.K., Karageorgopoulos, D.E., et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 35 (2010), 194–199.
7. [7] Dalfino, L., Puntillo, F., Mosca, A., Monno, R., Spada, M.L., Coppolecchia, S., et al. High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 54 (2012), 1720–1726.
8. [8] Garonzik, S.M., Li, J., Thamlikitkul, V., Paterson, D.L., Shoham, S., Jacob, J., et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55 (2011), 3284–3294.
9. [9] Bellomo, R., Ronco, C., Kellum, J.A., Mehta, R.L., Palevsky, P., Acute Dialysis Quality Initiative Workgroup. Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8 (2004), R204–12.
10. [10] Forrest, A., Silveira, F.P., Thamlikitkul, V., Garonzik, S.M., Mandragos, K., Shoham, S., et al. Toxicodynamics (TD) for colistin-associated changes in creatinine clearance (CrCl). In: 54th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC); 5–9 September 2014; Washington, DC. 2014, ASM Press, Washington (DC).
11. [11] Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing; twenty-fifth informational supplement. Document M100-S25. 2015, CLSI, Wayne (PA).
12. [12] Nation, R.L., Li, J., Cars, O., Couet, W., Dudley, M.N., Kaye, K.S., et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis 15 (2015), 225–234.